Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA117239 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Genome-wide methylation analyses in glioblastoma multiforme (GBM)
| PRJNA219380 | ENA
Project description:Glioblastoma multiforme (GBM) is a highly malignant brain cancer, and microglial cells play a critical role in its progression. Activation of microglia can either promote or inhibit GBM growth depending on the stage of tumour development and on the microenvironment. As current treatments for GBM have limited efficacy, there is an urgent need to develop novel strategies based on nanoplatforms for drug delivery and efficient targeting. This study investigated the microglial response and the therapeutic efficacy of dual cell membrane-coated and doxorubicin-loaded hexagonal boron nitride nanoplatelets, tested on human microglia and GBM cells. The results showed promising therapeutic effects on glioma cells and an M2 microglia polarization, highlighted through proteomic analysis.
2024-01-26 | PXD043557 | Pride
Project description:Genetic diversity of propagating/stem cells in glioblastoma multiforme (GBM)
| PRJNA193175 | ENA
Project description:The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.
| 2185625 | ecrin-mdr-crc
Project description:Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal brain tumors. BORIS (CTCFL) functions as an epigenetic and transcriptional regulator implicated in multiple cancers; however, its role in GBM is poorly understood. To explore its regulatory function, we performed ChIP-seq profiling in U87MG cells.
2026-01-30 | E-MTAB-15935 | biostudies-arrayexpress
Project description:Sixty Glioblastoma Multiforme (GBM) samples obtained from surgical excision with OS and PFS
| PRJNA299290 | ENA
Project description:glioblastoma multiforme genomic profiling by single nucleotide polymorphism microarray<br><br>Human GBM (glioblastoma multiforme)cell lines (U87, U118, U138, U343, U373, T98G) were maintained in Dulbecco's modified Eagle's medium with 10 % fetal calf serum, 10 U/ml penicillin-G, and 10 mg/ml streptomycin. All cells were incubated at 37 oC in 5% CO2.<br><br>Four primary GBM explants were established from patients with glioblastoma multiforme undergoing surgery as following described: Tumor specimens were immediately transported to the laboratory, finely minced to single cell suspension and cultured in complete medium [Ham's F-12/DME High Glucose medium containing 10% fetal calf serum, 10 U/ml penicillin-G, and 10 mg/ml streptomycin and 2 mM glutamax-1 into 100 cm2 tissue culture plastic dishes the second passage. All cells were incubated at 37 oC in 5% CO2.<br><br>GBM (glioblastoma multiforme) tissue samples were quick frozen. <br><br>Standard proteinase K-phenol-chloroform extraction method was used to extract DNA from GBM samples, cell lines and explants.<br><br>The matched peripheral blood data can be used as normalized data for their matched tumor tissue data. <br><br>The cell lines samples and two explants without normalized data, but they can be normalized by one of the peripheral blood DNA data.
2009-01-13 | E-MEXP-1330 | biostudies-arrayexpress
Project description:A Cartes d'Identite des Tumeurs (CIT) project from the French National League Against Cancer (http://cit.ligue-cancer.net ) 25 glioblastoma multiforme tumors hybridized on Illumina SNP and Affymetrix gene expression arrays. Project leader : François DUCRAY (francois.ducray@chu-lyon.fr). CIT Analysis : Julien LAFFAIRE (laffairej@ligue-cancer.net). Note: PFS : progression-free survival, OS: Overall Survival,BCNU : Carmustine (chemotherapy agent). RESPONDER: if the patient has shown or not shown a response to the treatment (Bevacizumab (Avastin) plus Irinotecan). Progression during : If the disease has progressed (cancer relapse or patient's death); otherwise (patient is alive without relapse).
2013-01-15 | E-MTAB-951 | biostudies-arrayexpress
Project description:Glioblastoma multiforme (GBM) is the most aggressive brain cancer, characterized by a rapid and drug-resistant progression. GBM “builds” around its primary core a genetically heterogeneous tumor-microenvironment (TME), recruiting surrounding healthy brain cells by releasing various intercellular signals. Glioma-associated microglia (GAM) represent the largest population of collaborating cells, which, in the TME, usually exhibit the anti-inflammatory M2 phenotype, thus promoting an immunosuppressing environment that helps tumor growth. Conversely, “classically activated” M1 microglia could provide pro-inflammatory and anti-tumorigenic activity, expected to exert a beneficial effect in defeating glioblastoma. In this work, we developed a targeted anti-glioma immunotherapy, based on pro-inflammatory modulation of the GAM phenotype, through a controlled and localized electrical stimulation. The proposed strategy relies on the excitation through the remote application of ultrasound of polymeric piezoelectric nanoparticles, coated with GBM cell membrane extracts to allow homotypic targeting. Such camouflaged nanotransducers locally generate electrical cues on GAM membranes, ultimately activating their M1 phenotype, and thus triggering a significant anti-cancer activity. Collected findings open new perspectives in the modulation of immune cell activities though “smart” nanomaterials and, more specifically, provide an innovative tool in glioma immunotherapy.
2026-07-16 | PXD046051 | Pride
Project description:<p>Glioblastoma multiforme (GBM) is highly aggressive, with treatment resistance and recurrence driven by metabolically plastic glioma stem cells (GSCs). Inspired by brown adipose tissue (BAT) thermogenesis, researchers transplanted BAT-derived mitochondria (BA-Mito) into GSCs, reducing stemness markers and enhancing chemosensitivity to temozolomide (TMZ). To improve delivery, a CD133 aptamer-modified liposome-coated mitochondrial system (Apt/Lipo-Mito Gel) was developed, using alginate hydrogel as a post-surgical reservoir for sustained mitochondrial release, offering a novel metabolic therapy strategy for GBM.</p>
2025-08-27 | MTBLS12901 | MetaboLights